Papajík T., Raida L., Faber E., Indrák K.:
B-cell chronic lymphocytic leukemia. Part V. Stem cell transplantation
|
100 |
Mayer J.1, Schwarz J.2, Doubek M.1, Brychtová Y.1, Brejcha M.3, Pospíšilová Š.1, Trbušek M.1, Kuhrová V.1:
What can we currently learn from new prognostic markers of chronic lymphocytic leukemia in the
everyday haematological practice?
|
106 |
Janíková A.1, Bolčák K.2, Mayer J.1, Néméthová D.3, Staníček J.2 :
Clinical value of 18F-FDG-positron
emission tomography in follicular lymphoma
|
117 |
Zemanová M.1, Ščudla V.1, Pour L.2, Gregora E.3, Pavlíček P.3, Minařík J.1, Pika T.1, Bačovský J.1, Adam Z.2, Hájek R.2:
CTD regimen (cyclophosphamide, thalidomide, dexamethasone) in the treatment of relapsed
or refractory multiple myeloma
|
126 |
Mayer J.1, Klamová H.1, Žáčková D.1, Doubek M.1, Cetkovský P.1, Krejčí M.1, Dvořáková D.1 :
Resistance
to imatinib and the possibilities of use of the dose escalation of the drug in patients with chronic myeloid leukemia
|
133 |
Jindra P.1,2, Ambrůzová Z.3, Mrázek F.3, Pittrová H.1, Navrátilová J.1, Steinerová K.1,2 a Koza V.1,2:
Confirmatory
HLA typing results as an indicator of quality of the HLA typing of the door pool: Czech national marrow
doors registry (CNMDR) experience
|
142 |
Lysák D.1, Navrátilová J.2:
G-CSF in healthy donors. Safe or harmful?
|
149 |
Indrák K.1, Papajík T.1, Faber E.1, Hájek R.2, Čermák J.3, Raida L.1, Hubáček J.1, Szotkowski T.1, Mužík J.4 a Dušek L.4:
Proposal for population – oriented registration of hemato-oncologic diagnoses based on
1999 WHO cancer classification analysis of general treatment options and on requirements of the Czech National
Cancer Registry
|
154 |
Turek P.:
Production and use of blood components in Czech Republic in the year 2006
|
159 |
